Group 1 - The core viewpoint of the article emphasizes the performance and characteristics of the "brokerage golden stocks" pool, highlighting its ability to track the performance of mixed equity funds and the strong selection capabilities of industry analysts [2][9][32] - In May 2025, the top-performing stocks in the brokerage golden stock pool included Mankalon, Chaohongji, and Kexing Pharmaceutical, with monthly returns of 10.78%, 7.30%, and 5.70% respectively [3][8] - Year-to-date, Northeast Securities, Huaxin Securities, and Dongxing Securities ranked highest in returns, achieving 45.28%, 40.52%, and 39.15% respectively, while the mixed equity fund index returned 3.37% and the CSI 300 index returned -2.41% [7][10] Group 2 - As of June 3, 2025, 43 brokerages published golden stocks, resulting in a total of 286 unique A-shares after deduplication [19] - The current allocation of golden stocks is highest in the machinery (9.56%), pharmaceuticals (9.04%), electronics (8.01%), basic chemicals (7.75%), and food and beverage (6.46%) sectors [23] - The brokerage golden stock pool has a higher exposure to small-cap stocks this month, indicating a shift in investment style [19][23] Group 3 - The performance of the brokerage golden stock performance enhancement portfolio showed an absolute return of 0.99% for the month and 4.97% year-to-date, outperforming the mixed equity fund index by 1.61% [28][29] - The article highlights the strong alpha generation capability of the brokerage golden stocks, which can provide significant investment opportunities [32][33] - The article also discusses the interaction between brokerage analysts and public fund managers, indicating that stocks recommended by multiple analysts tend to receive higher market attention [9][21]

Core Insights - In 2024, China's innovative drug license-out transaction amount exceeded $51.9 billion, with emerging technology pipelines like ADC, bispecific antibodies, and CGT accounting for over 30% of global research projects, indicating China's transition from a "technology follower" to an "innovation source" [2] - The ongoing unmet clinical needs globally are driving multinational corporations (MNCs) to accelerate collaborations with Chinese pharmaceutical companies [2] - Despite the optimistic outlook, companies must focus on adapting to changing international policies and optimizing resource allocation to balance innovation and commercialization efficiency during their internationalization journey [2] Event Overview - The 2025 CPHI China Biotech Exhibition will feature high-quality thematic conferences, including the "10th CPHI Biopharmaceutical Forum" and "New Forces, New Journey - CPHI Innovative Drug Going Global Forum," gathering industry leaders from companies like BeiGene, Zai Lab, and Biocon [2][5] - The event aims to analyze the global biopharmaceutical industry landscape, from regulation to research, and promote collaboration across the entire chain from laboratory research to large-scale production [5] Conference Agenda Highlights - The conference will take place from June 24-25, 2025, at the Shanghai New International Expo Center, featuring sessions on topics such as the development trends of Chinese biopharmaceuticals, the future of biomanufacturing, and strategies for international cooperation [6][11] - Keynote speakers include experts from various sectors, discussing clinical trial strategies, market trends, and the impact of capital on innovation in the biopharmaceutical field [7][12] Focus Areas - The event will emphasize "frontier therapies," particularly in the fields of peptide drugs and cell and gene therapy (CGT), aiming to connect research, production, clinical applications, and internationalization [21] - The conference will also explore the opportunities and challenges of Chinese innovative drugs entering international markets, particularly in Southeast Asia, Latin America, and the Middle East [12][13]

Economic Indicators - In May, China's manufacturing Purchasing Managers' Index (PMI) increased by 0.5 percentage points, indicating an improvement in manufacturing sentiment [1] - The export container freight index has rebounded, and port cargo throughput remains at a high level, suggesting a stable economic outlook for the second quarter [1] A-Share Market Trends - After a high and subsequent pullback in May, the A-share market is expected to focus on core assets in June, with institutions suggesting a cautious approach due to potential downward pressure [2] - Institutions recommend maintaining dividend assets as a base while exploring opportunities in growth and consumption sectors, particularly in banking, computing power industry, card games, and innovative pharmaceuticals [2] Hong Kong Stock Market - The Hong Kong stock market showed a rebound after a decline, with significant strength in consumer services, durable goods, and medical equipment sectors [3] - Notable stock performances include a rise of over 7% for Mixue Group and over 4% for Pop Mart, indicating a potential upward trend in the market driven by domestic policy support [3] A-Share Company Name Changes - Over 60 A-share companies have undergone name changes since 2025, reflecting business adjustments, strategic transformations, or capital operations [4] - The trend indicates companies' proactive adaptation to market changes and the influence of industry cycles and policy environments on capital allocation [4] A-Share Market Resilience - In May, the A-share market showed resilience, with most major indices rising, supported by improved risk appetite and regulatory measures [5] - The market is expected to remain in a recovery phase in June, with a focus on technology sectors for investment opportunities [5] Fundraising in Public Funds - June is witnessing a "small peak" in new public fund launches, with 89 funds entering the market, 70% of which are equity products [6] - Major fund companies are actively launching multiple new funds, indicating strong investor interest in equity funds [6] Shenzhen Venture Capital Industry - The Shenzhen venture capital industry is experiencing a recovery, with a notable increase in investments in hard technology projects, particularly in aerospace, semiconductors, and biotechnology [8] - The number of projects in these sectors has seen significant year-on-year growth, indicating a strong focus on technological innovation [8] Innovation Drug Sector Performance - The Chinese innovative drug sector is undergoing a significant value reassessment, with several stocks experiencing over 200% increases since the beginning of the year [9] - Despite a recent pullback in the Hong Kong innovative drug sector, the medium-term outlook remains positive for continued growth [9] Chemical Industry Response to OPEC+ - The Chinese chemical industry is facing pressures from both upstream supply and downstream demand due to OPEC+'s decision to increase production [10] - Companies are employing futures hedging strategies to mitigate risks associated with price volatility [10] Risk Mitigation in Listed Companies - As of June 3, 28 listed companies have successfully "delisted" or "removed their special treatment" this year, primarily through financial improvements and internal control repairs [11] - The trend indicates potential investment opportunities in companies that demonstrate recovery characteristics [11] ETF Market Growth - The public ETF market has shown strong growth, with 104 private equity institutions heavily investing in newly listed ETFs, particularly those focused on technology and cash flow [12] - This reflects a growing interest from private equity in diversified investment strategies [12] Consumer Upgrade Policies - The "trade-in" policy has significantly boosted sales, with total sales reaching 1.1 trillion yuan and over 1.75 billion subsidies issued to consumers [13] - The policy is driving consumption growth and encouraging companies to innovate and upgrade their products [14]

作为券商月度策略的精华，券商每月金股受到市场关注。 回望5月，最牛金股当月涨幅高达52%。刚刚出炉的6月金股中，电子、医药生物、汽车、食品饮料等板块的金 股数量居前，港股标的关注度显著抬升。 展望6月，不少券商认为，当前弱美元趋势下，人民币资产有望受益，A股中长期有望震荡上行。 医药板块金股5月收益率领先 从5月金股表现来看，由长城证券推荐的药师帮（9885.HK）以52%的月涨幅排名第一；由华西证券推荐的曼 卡龙（300945.SZ）、由天风证券推荐的潮宏基（002345.SZ）紧随其后，分居第二、第三，月涨幅均超45%。 展望6月行情，不少券商认为，当前弱美元趋势下，人民币资产有望受益，A股中长期有望震荡上行。 中国银河证券策略首席蔡芳媛认为，6月A股市场将大概率震荡上行，建议把握波动中的确定性，关注消费、 科技、红利三条主线。随着经济复苏的持续叠加国内政策保持积极态势，并且监管层多次发声表达对A股市场 的呵护，人民币资产作为美国信用的一种对冲可能受益，多因素共振将持续助力市场风险偏好提升。 东吴证券认为，新一轮"东升西落"交易可能很快来临。美元周期是"东升西落"交易的关键，从历史经验看，在 全球流动性宽 ...

Core Viewpoint - The Chinese innovative drug industry is undergoing an unprecedented value reassessment, with a recent acceleration in this trend [1][2][6] Group 1: Market Performance - As of May 30, 2023, stocks of Rongchang Biologics and 3SBio have surged over 200% since the beginning of the year, with several other innovative drug stocks doubling in price [1] - The Hong Kong innovative drug sector experienced a significant pullback on June 2, attributed to profit-taking after substantial gains [2][3] - Various innovative drug-themed funds have rebounded significantly, with some products showing annual increases exceeding 50% [1][2] Group 2: Fund Performance - Innovative drug ETFs have dominated the performance rankings, with top performers like Huatai-PB's Hang Seng Innovative Drug ETF rising by 42.84% year-to-date [2] - Actively managed innovative drug funds have also seen substantial gains, with Longview Medical Industry Select Fund and Yongying Medical Innovation Fund increasing by 64.42% and 55.34% respectively [2] Group 3: Clinical Developments - On May 30, Summit Therapeutics reported disappointing results from a Phase III trial for its PD-1/VEGF dual antibody, leading to a 30% drop in its stock price [3] - Concerns over clinical data from certain companies have contributed to market pullbacks, with some fund managers suggesting that profit-taking is a factor [3] Group 4: Global Expansion - A notable trend is the increasing competitiveness and attractiveness of Chinese innovative drug companies in the global pharmaceutical industry [5] - In 2024, China is expected to account for 30% of global transactions involving upfront payments exceeding $50 million, indicating a growing trend in overseas licensing deals [5] Group 5: Future Outlook - Multiple fund managers believe that the innovative drug sector has opportunities across valuation, fundamentals, and industry cycles, suggesting a potential for mid-term sustainability [6] - The current valuation levels of innovative drugs are considered relatively low, with expectations of a shift in valuation systems as more companies report profits [6]

5月份，格力电器和江苏银行均获得6家券商推荐，当月股价分别上涨4.11%、8.07%；海大集团获得5家 券商推荐，当月股价上涨9.25%。 券商金股组合指数的表现也能反映出券商研究所的业务实力。5月份，有26只券商金股组合指数实现上 涨，其中14只券商金股组合指数当月涨超3%。"国元证券金股指数"当月上涨11.91%，涨幅居首；"国盛 证券金股指数""华创证券金股指数""浙商证券金股指数"当月分别上涨5.29%、4.8%、4.63%。 本报记者 周尚伃 见习记者 于宏 近日，券商密集发布6月份金股名单。截至6月2日，券商已合计推荐132只金股，其中，亚钾国际被推荐 次数暂居第一，已获得4家券商推荐。从行业分布来看，上述132只金股中，来自工业和信息技术行业 （Wind一级行业，下同）的金股数量较多。展望6月份市场行情，多位券商分析师预计，科技、消费板 块仍为投资主线。 5月份最强金股涨超45% 回顾5月份，券商5月份合计推荐的272只金股中，132只金股当月股价实现上涨，占比48.53%。32只金 股当月股价涨幅超10%，占比11.76%。 具体来看，5月份涨幅最高的金股为天风证券推荐的潮宏基，当月涨幅为45 ...

近一周机构调研个股数量有530多只，拓荆科技获调研机构数最多。拓荆科技获179家机构调研。此外， 还有金帝股份（603270）、华丰科技、科兴制药、聚辰股份等个股近一周获较多机构调研；其中科兴制 药等个股属于近期火爆的创新药板块。(人民财讯) ...

Market Overview - On May 30, the three major A-share indices collectively declined, with the Shanghai Composite Index falling by 0.47% to 3347.49 points, the Shenzhen Component Index down by 0.85% to 10040.63 points, and the ChiNext Index decreasing by 0.96% to 1993.19 points [1]. Fund Manager Changes - In the past 30 days (April 30 to May 30), a total of 513 fund managers have left their positions across various funds. On May 30 alone, 39 funds announced changes in fund managers, with 6 leaving due to job changes and 2 due to personal reasons [1]. - Notable fund managers who left include those managing a total of 15 funds and 24 funds respectively, indicating significant turnover that could impact fund performance [1]. New Fund Managers - New fund managers have taken over several funds, including Yan Peixian at China Europe Fund, managing assets totaling 12.365 billion yuan, with a notable return of 87.82% over 10 years and 49 days on the China Europe Pure Bond One Year A fund [3]. - Other new appointments include managers for the China Europe Xingyue Bond A and C funds, as well as the China Europe Xingying One Year Open Bond Initiation fund [3]. Fund Research Activity - In the last month, Huaxia Fund conducted the most company research, engaging with 67 listed companies, followed by Bosera Fund with 62 and Harvest Fund with 60 [5]. - The most researched industry was specialized equipment, with 278 instances of fund company inquiries, followed by the medical device sector with 210 inquiries [5]. Individual Stock Research - The most researched stock in the past month was Zhaowei Electromechanical, with 88 fund management companies participating in the research, followed by Anji Technology and Heng'erda with 82 and 80 respectively [6]. - In the past week (May 23 to May 30), Huafeng Technology led with 33 fund institutions conducting research, followed by Jucheng Co., Kexing Pharmaceutical, and Aisen Co. with 27, 24, and 17 respectively [6].

Market Overview - On May 30, the last trading day before the Dragon Boat Festival, the market opened lower and experienced weak fluctuations, with the North Stock 50 index rising by 0.25% while the Shanghai Composite Index fell by 0.31% to 3353.07 points [1] - The total trading volume of A-shares for the half day was 771.57 billion yuan [1] Monetary Policy - The People's Bank of China announced a 7-day reverse repurchase operation of 291.1 billion yuan at a fixed rate of 1.40%, with a net injection of 148.6 billion yuan for the day [1] Industry Developments - The China Securities Association is formulating a special evaluation method for securities companies, focusing on contributions to key areas such as technology finance, green finance, and digital finance [1] Pharmaceutical Sector Performance - The pharmaceutical sector saw significant gains, with stocks like Ruizhi Pharmaceutical and Huana Pharmaceutical hitting a 20% limit up, while other related sectors such as CRO and brain-computer interface also experienced upward trends [2] Sector Performance Data - The top performing sectors included: - Chicken: +2.55% - Innovative Drugs: +2.52% - Pork: +2.47% - Immune Therapy: +1.94% - COVID-19 Drug Concept: +1.94% [3] Investment Outlook for Innovative Drugs - The investment value of innovative drugs is viewed positively due to ongoing supportive policies, improving payment conditions, and upgrading research capabilities of supply-side enterprises [4] - Companies with strong innovation capabilities and rich product pipelines are expected to benefit in the long term from the continuous promotion of bulk purchasing of drugs and consumables [4] Company Profiles - **Huana Pharmaceutical**: A high-tech enterprise focused on the R&D, production, and sales of chemical drugs and traditional Chinese medicine, with a promising antidepressant drug ZG001 [7] - **Kexing Pharmaceutical**: An innovative biopharmaceutical company engaged in the R&D and sales of recombinant protein drugs and micro-ecological preparations, with a strong international presence [7] - **Guanhao Biological**: Actively advancing the application for a human genetic resource sample library to support innovation in drug development and health services [7] - **Haichuang Pharmaceutical**: An international innovative drug company focusing on cancer and metabolic diseases, utilizing PROTAC technology for drug development [8]

中国基金报记者安曼 端午节前最后一个交易日，美国关税政策反复，亚太市场早盘整体走低。 【导读】银行股逆市拉升，创新药板块批量涨停 消息落地后，银行股逆市拉升。 杭州银行、成都银行双双创下历史新高。 中信银行涨超3%，中小银行涨幅居前。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 601998 | 中信银行 | 7.92 | 0.24 | 3.13% | | 601077 | 渝农商行 | 7.28 | 0.17 | 2.39% | | 601528 | 瑞丰银行 | 5.62 | 0.12 | 2.18% | | 002958 | 青农商行 | 3.43 | 0.07 | 2.08% | | 600000 | 浦发银行 | 12.39 | 0.22 | 1.81% | | 603323 | 苏农银行 | 5.98 | 0.10 | 1.70% | | 002948 | 青岛银行 | 4.98 | 0.08 | 1.63% | | 601825 | 沪农商行 | 8.93 | 0.14 | 1.59% | | 601838 | ...